EA201400521A1 - Гетероциклические соединения, лекарственные средства, содержащие указанные соединения, их применение и способы их получения - Google Patents

Гетероциклические соединения, лекарственные средства, содержащие указанные соединения, их применение и способы их получения

Info

Publication number
EA201400521A1
EA201400521A1 EA201400521A EA201400521A EA201400521A1 EA 201400521 A1 EA201400521 A1 EA 201400521A1 EA 201400521 A EA201400521 A EA 201400521A EA 201400521 A EA201400521 A EA 201400521A EA 201400521 A1 EA201400521 A1 EA 201400521A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
methods
receiving
medicines containing
indicated
Prior art date
Application number
EA201400521A
Other languages
English (en)
Other versions
EA025158B1 (ru
EA025158B9 (ru
Inventor
Армин Хеккель
Сара Фраттини
Дитер Хампрехт
Йёрг Клей
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201400521A1 publication Critical patent/EA201400521A1/ru
Publication of EA025158B1 publication Critical patent/EA025158B1/ru
Publication of EA025158B9 publication Critical patent/EA025158B9/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

В заявке описаны соединения общей формулы (I)и их таутомеры и соли, предпочтительно их фармацевтически приемлемые соли с неорганическими или органическими кислотами и основаниями, которые обладают ценными фармакологическими характеристиками, в особенности ингибирующим воздействием на эпителиальные натриевые каналы, их применение для лечения заболеваний, в особенности заболеваний легких и дыхательных путей.
EA201400521A 2011-11-02 2012-10-29 Гетероциклические соединения, лекарственные средства, содержащие указанные соединения, их применение и способы их получения EA025158B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11187553 2011-11-02
PCT/EP2012/071352 WO2013064450A1 (en) 2011-11-02 2012-10-29 Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof

Publications (3)

Publication Number Publication Date
EA201400521A1 true EA201400521A1 (ru) 2014-09-30
EA025158B1 EA025158B1 (ru) 2016-11-30
EA025158B9 EA025158B9 (ru) 2018-03-30

Family

ID=47073464

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201400521A EA025158B9 (ru) 2011-11-02 2012-10-29 Гетероциклические соединения, лекарственные средства, содержащие указанные соединения, их применение и способы их получения

Country Status (34)

Country Link
US (4) US8759349B2 (ru)
EP (1) EP2773633B1 (ru)
JP (1) JP6091513B2 (ru)
KR (1) KR102006612B1 (ru)
CN (2) CN106279110B (ru)
AP (1) AP2014007670A0 (ru)
AU (1) AU2012331274B2 (ru)
BR (1) BR112014010583A2 (ru)
CA (1) CA2854217C (ru)
CL (1) CL2014001047A1 (ru)
CO (1) CO6940429A2 (ru)
CY (1) CY1120974T1 (ru)
DK (1) DK2773633T3 (ru)
EA (1) EA025158B9 (ru)
EC (1) ECSP14001929A (ru)
ES (1) ES2645744T3 (ru)
GE (2) GEP20186880B (ru)
HR (1) HRP20171614T1 (ru)
HU (1) HUE034929T2 (ru)
IL (1) IL232035A (ru)
LT (1) LT2773633T (ru)
ME (1) ME02905B (ru)
MX (1) MX348522B (ru)
NO (1) NO2773633T3 (ru)
PE (1) PE20141607A1 (ru)
PH (1) PH12014500970B1 (ru)
PL (1) PL2773633T3 (ru)
PT (1) PT2773633T (ru)
RS (1) RS56498B1 (ru)
SG (1) SG11201401907TA (ru)
SI (1) SI2773633T1 (ru)
TN (1) TN2014000180A1 (ru)
UA (1) UA115868C2 (ru)
WO (1) WO2013064450A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
NO2773633T3 (ru) * 2011-11-02 2017-12-30
CA2915633A1 (en) * 2013-07-02 2015-01-08 The California Institute For Biomedical Research Compounds for treatment of cystic fibrosis
WO2015003958A1 (en) * 2013-07-08 2015-01-15 Boehringer Ingelheim International Gmbh Amiloride-type compounds as inhibitors in epithelial sodium channels for the treatment of diseases of the lungs and airways
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
SG11201703284XA (en) 2014-10-24 2017-06-29 Ono Pharmaceutical Co Kcnq2-5 channel activator
CN107405505A (zh) * 2015-01-07 2017-11-28 加州生物医学研究所 用于治疗囊性纤维化的化合物
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
GB201717051D0 (en) 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
GB201808093D0 (en) 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
AU2021341508A1 (en) 2020-09-10 2023-05-25 Precirix N.V. Antibody fragment against fap
CN112107580A (zh) * 2020-09-29 2020-12-22 北京鑫开元医药科技有限公司 一种脾酪氨酸激酶抑制剂的制剂组合物及其制备方法
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting
WO2024243025A1 (en) * 2023-05-19 2024-11-28 Ikena Oncology, Inc. Naphthyl-substituted pyrido[4,3-d]pyrimidines and related compounds and their use in treating medical conditions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6812003A (ru) 1967-09-07 1969-03-11
US3953476A (en) 1971-12-27 1976-04-27 Merck & Co., Inc. 3-Amino-5-sulfonylbenzoic acids
ATE390414T1 (de) 1999-07-19 2008-04-15 Univ North Carolina Arzneimittelwirkstoffe mit zwei kovalent verknüpften wirkstoffgruppen (natriumkanalblocker/p2y2 rezeptor agonist) zur behandlung von schleimhäuten
JP2003520042A (ja) 2000-01-24 2003-07-02 アイシス・ファーマシューティカルス・インコーポレーテッド 誘導性一酸化窒素シンターゼ発現のアンチセンスモジュレーション
CA2575670A1 (en) 2004-08-18 2006-03-02 Michael R. Johnson Aliphatic amide & ester pyrazinoylguanidine sodium channel blockers
GB0526244D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
EP2484308A1 (en) * 2006-07-24 2012-08-08 International Stem Cell Corporation Synthetic cornea from retinal stem cells
EP2332933A1 (en) * 2007-05-07 2011-06-15 Novartis AG Epithelial sodium channel (ENaC) inhibitors
BRPI0820669A2 (pt) 2007-12-10 2020-08-04 Novartis Ag compostos orgânicos
MX2010012441A (es) * 2008-05-13 2010-12-06 Novartis Ag Derivados de acido 3,5-diamino-6-cloro-pirazin-2-carboxilico y su uso como bloqueadores del canal de sodio epitelial para el tratamiento de enfermedades de las vias respiratorias.
KR20110040818A (ko) 2008-06-10 2011-04-20 노파르티스 아게 상피 나트륨 채널 차단제로서의 피라진 유도체
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
US9050339B2 (en) 2010-09-17 2015-06-09 Novartis Ag Pyrazine derivatives as ENaC blockers
SI2723176T1 (sl) 2011-06-27 2017-09-29 Parion Sciences, Inc. Kemijsko in metabolno stabilni dipeptid, ki ima močno aktivnost blokiranja natrijevega kanala
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
AU2012331275A1 (en) 2011-11-02 2014-04-03 Boehringer Ingelheim International Gmbh Novel process for the preparation of acylguanidines and acylthioureas
NO2773633T3 (ru) * 2011-11-02 2017-12-30

Also Published As

Publication number Publication date
AU2012331274A1 (en) 2014-04-03
EP2773633B1 (en) 2017-08-02
SG11201401907TA (en) 2014-05-29
AU2012331274B2 (en) 2017-06-08
CN106279110A (zh) 2017-01-04
RS56498B1 (sr) 2018-01-31
SI2773633T1 (sl) 2017-11-30
HUE034929T2 (en) 2018-03-28
CL2014001047A1 (es) 2014-11-07
CN106279110B (zh) 2019-12-10
CA2854217C (en) 2019-12-31
CO6940429A2 (es) 2014-05-09
NO2773633T3 (ru) 2017-12-30
US20140228374A1 (en) 2014-08-14
HK1196819A1 (zh) 2014-12-24
GEAP201813485A (en) 2018-04-10
NZ622469A (en) 2016-08-26
PL2773633T3 (pl) 2018-01-31
GEP20186880B (en) 2018-07-25
TN2014000180A1 (en) 2015-09-30
EP2773633A1 (en) 2014-09-10
US20180194747A1 (en) 2018-07-12
US8759349B2 (en) 2014-06-24
JP6091513B2 (ja) 2017-03-08
PE20141607A1 (es) 2014-11-23
IL232035A (en) 2017-05-29
JP2014534222A (ja) 2014-12-18
CN104024244B (zh) 2016-09-14
MX2014005166A (es) 2014-05-28
MX348522B (es) 2017-06-16
KR102006612B1 (ko) 2019-08-02
CN104024244A (zh) 2014-09-03
HRP20171614T1 (hr) 2017-12-01
EA025158B1 (ru) 2016-11-30
ECSP14001929A (es) 2015-11-30
LT2773633T (lt) 2017-11-10
DK2773633T3 (da) 2017-11-13
BR112014010583A2 (pt) 2020-04-22
PH12014500970A1 (en) 2014-06-09
KR20140085498A (ko) 2014-07-07
CA2854217A1 (en) 2013-05-10
ME02905B (me) 2018-10-20
PT2773633T (pt) 2017-11-14
IL232035A0 (en) 2014-05-28
UA115868C2 (uk) 2018-01-10
US20130109697A1 (en) 2013-05-02
CY1120974T1 (el) 2019-12-11
PH12014500970B1 (en) 2017-10-06
ES2645744T3 (es) 2017-12-07
AP2014007670A0 (en) 2014-05-31
WO2013064450A1 (en) 2013-05-10
US9920035B2 (en) 2018-03-20
US20150336933A1 (en) 2015-11-26
EA025158B9 (ru) 2018-03-30

Similar Documents

Publication Publication Date Title
UA115868C2 (uk) Гетероциклічні сполуки, лікарські засоби, які містять зазначені сполуки, їх застосування і способи їх одержання
UA115320C2 (uk) Інгібітори кінази
EA201491671A1 (ru) Гетероциклильные соединения
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
EA201792116A1 (ru) Ингибитор янус-киназы
EA201100613A1 (ru) Конденсированные, спироциклические гетероароматические соединения для лечения бактериальных инфекций
EA201001368A1 (ru) Гетероциклические производные мочевины и способы их применения-211
UA104489C2 (ru) Соединения для лечения дислипидемии и родственных болезней
EA201591195A1 (ru) Новые хинолоновые производные
CO6361926A2 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), produccion y uso de los mismos como productos medicinales
EA201690888A1 (ru) Новые гетероциклические соединения
PH12014501278A1 (en) Kinase inhibitors
BR112014008783A2 (pt) compostos para o tratamento e profilaxia da doença causada por vírus sincicial respiratório
EA201591362A1 (ru) Соединения и способы лечения бактериальных инфекций
NZ626618A (en) Hydroxamic acid derivatives and uses thereof
EA201490750A1 (ru) Применение глутарилгистамина для лечения заболеваний дыхательных путей
MX2011012384A (es) Derivados nitrilo y sus usos y composiciones farmaceuticas.
EA201491651A1 (ru) Новые соединения для лечения дислипидемии и родственных заболеваний
EA201400522A1 (ru) Новый способ получения ацилгуанидинов и ацилтиомочевин
EA201400786A1 (ru) Карбоциклические нуклеозиды, их фармацевтическое применение и композиции
TN2014000218A1 (en) Kinase inhibitors
TH134961A (th) อนุพันธ์ควินาโซลีนสำหรับการรักษาการติดเชื้อไวรัสและโรคเพิ่มเติม
AR088107A1 (es) Derivados de anilinopirimidina y su uso como inhibidores de quinasas p38
CU20100172A7 (es) Derivados heterocíclicos de urea y métodos de uso de los mismos-211
TH154903A (th) อนุพันธ์แอลคิลไพริมิดีนสำหรับการรักษาการติดเชื้อไวรัสและโรคอื่นๆ

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ RU